Cogent Biosciences Inc
NASDAQ:COGT
Intrinsic Value
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of COGT.
Cogent Biosciences Inc's market capitalization is 697.3m USD.
COGT stock price is 6.71 USD.
COGT.
COGT. Open DCF Valuation
COGT. Open Relative Valuation
COGT has upside potential of 154% compared to the average analyst price target.
Open Wall St Estimates
COGT's ROE (Return on Equity) has significantly increased in the last 3 years from -146% to -75%, and is approaching profitability.
COGT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 162% to -572%, and is approaching profitability.
COGT has negative Operating Income for the last twelve months.
COGT has negative Net Income for the last twelve months.
COGT's ROE (Return on Equity) for the past 12 months is negative and is equal to -75%.
COGT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -572%.
COGT's Altman Z-Score is very low and is equal to 1.58.
COGT has negative Free Cash Flow for the last twelve months.
COGT has negative three-year average ROE (Return on Equity): -80%. The company is not efficient at transforming stockholders' equity into net income.
COGT has negative three-year average ROIC (Return on Invested Capital): -732%. The company is not efficient at using invested capital to generate operating income.
COGT's short-term assets (271m USD) exceed its short-term liabilties (38m USD).
COGT's long-term assets (313m USD) exceed its long-term liabilties (56m USD).
COGT's D/E (Debt to Equity) is very low and is equal to 0.
Fundamental Analysis
Cogent Biosciences Inc
Balance Sheet Decomposition
Cogent Biosciences Inc
| Current Assets | 270.8m |
| Cash & Short-Term Investments | 265.7m |
| Other Current Assets | 5.1m |
| Non-Current Assets | 42.7m |
| Long-Term Investments | 7.5m |
| PP&E | 30.3m |
| Other Non-Current Assets | 4.9m |
| Current Liabilities | 38.2m |
| Accounts Payable | 10.7m |
| Accrued Liabilities | 27.1m |
| Other Current Liabilities | 441k |
| Non-Current Liabilities | 17.5m |
| Other Non-Current Liabilities | 17.5m |
Earnings Waterfall
Cogent Biosciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-208.1m
USD
|
|
Operating Income
|
-208.1m
USD
|
|
Other Expenses
|
15.7m
USD
|
|
Net Income
|
-192.4m
USD
|
Free Cash Flow Analysis
Cogent Biosciences Inc
What is Free Cash Flow?
COGT Profitability Score
Profitability Due Diligence
Cogent Biosciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Cogent Biosciences Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
COGT Solvency Score
Solvency Due Diligence
Cogent Biosciences Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Cogent Biosciences Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COGT Price Targets Summary
Cogent Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
COGT
is 17.03 USD
with a low forecast of 8.08 USD and a high forecast of 27.3 USD.
Ownership
COGT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
COGT Price
Cogent Biosciences Inc
| Average Annual Return | 61.08% |
| Standard Deviation of Annual Returns | 182.08% |
| Max Drawdown | -91% |
| Market Capitalization | 697.3m USD |
| Shares Outstanding | 103 913 000 |
| Percentage of Shares Shorted | 11.68% |
Company Profile
Cogent Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 77 full-time employees. The company went IPO on 2018-03-29. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The firm has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. The company also initiated Peak, a randomized, open-label, global Phase III clinical trial.
You don't have any saved screeners yet
